Cargando…
Bone Metastasis
Bone metastasis occurs in 60 to 85% of all breast, prostate, and lung cancer patients and is responsible for increasing morbidity. In Bone Metastasis: Experimental and Clinical Therapeutics, leading bone metastasis experts from around the world explain the molecular underpinnings of the process, rev...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Totowa, NJ :
Humana Press : Imprint: Humana,
2005.
|
| Edición: | 1st ed. 2005. |
| Colección: | Cancer Drug Discovery and Development,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-1-59259-892-2 | ||
| 003 | DE-He213 | ||
| 005 | 20220121005620.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100301s2005 xxu| s |||| 0|eng d | ||
| 020 | |a 9781592598922 |9 978-1-59259-892-2 | ||
| 024 | 7 | |a 10.1385/1592598927 |2 doi | |
| 050 | 4 | |a RC254-282 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Bone Metastasis |h [electronic resource] / |c edited by Gurmit Singh, Shafaat A. Rabbani. |
| 250 | |a 1st ed. 2005. | ||
| 264 | 1 | |a Totowa, NJ : |b Humana Press : |b Imprint: Humana, |c 2005. | |
| 300 | |a XIII, 344 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Cancer Drug Discovery and Development, |x 2196-9914 | |
| 505 | 0 | |a Fundamental Concepts -- Overview -- Parathyroid Hormone-Related Peptide and Malignancy -- Vitamin D and Vitamin D Analogs in Cancer Progression and Metastasis -- Role of TGF-? and IGF in Tumor Progression and Bone Metastases -- Biologic and Therapeutic Implications of Osteomimicry and Epithelial-Mesenchymal Transition in Prostate Cancer -- Roles of Immune-Cell-Derived Matrix Metalloproteinases in Tumor Growth and Metastasis -- Contribution of Osteopontin to the Development of Bone Metastasis -- Role of Interleukin-11 in Osteolytic Bone Metastasis -- Cell Adhesion Molecules in Tumor Metastasis -- PTHrP and Cancer -- Antithrombotics in Tumor Growth and Metastasis -- Therapeutic Strategies -- Challenges and Strategies in the Analysis of Multiple Events in Oncology -- Integrins -- Bone Metastasis and Pathological Fractures -- Role of Photodynamic Therapy for Bone Metastasis -- Docetaxel for Metastatic Cancer and Its Role in Combination Therapies for Advanced Prostate Cancer -- Use of Tetracyclines for Bone Metastases -- Role of Bisphosphonates in Skeletal Metastases -- Radiation Treatment of Bone Metastases. | |
| 520 | |a Bone metastasis occurs in 60 to 85% of all breast, prostate, and lung cancer patients and is responsible for increasing morbidity. In Bone Metastasis: Experimental and Clinical Therapeutics, leading bone metastasis experts from around the world explain the molecular underpinnings of the process, review current treatment approaches, and outline future therapeutic strategies. On the basic science side, the authors illuminate the role of various autocrine, paracrine, and immunological factors involved in the progression and establishment of bone metastases, highlighting the physiological processes that lead to bone degradation, pain, angiogenesis, and dysregulation of bone turnover. On the therapeutic side, the authors discuss various strategies that appear to have promise and are currently deployed in treatment or at the experimental stage. They show how the treatment of bone metastases may need to be individualized through a combination of surgical, radiation, and/or pharmacological maneuvers. Their analysis of various pharmacogenomic parameters and tissue environmental factors sets the stage for progress beyond the current standards of using radiation and/or bisphosphonates for palliation. State-of-the-art and innovative, Bone Metastasis: Experimental and Clinical Therapeutics elucidates for all those involved-whether in research or clinical treatment of bone-seeking cancers-the biological processes and therapeutic advances that are already generating significant improvement in the cancer clinic. | ||
| 650 | 0 | |a Oncology. | |
| 650 | 1 | 4 | |a Oncology. |
| 700 | 1 | |a Singh, Gurmit. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Rabbani, Shafaat A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9781617375453 |
| 776 | 0 | 8 | |i Printed edition: |z 9781588294036 |
| 830 | 0 | |a Cancer Drug Discovery and Development, |x 2196-9914 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1385/1592598927 |z Texto Completo |
| 912 | |a ZDB-2-SME | ||
| 912 | |a ZDB-2-SXM | ||
| 950 | |a Medicine (SpringerNature-11650) | ||
| 950 | |a Medicine (R0) (SpringerNature-43714) | ||